Phase 1 Study of RO7875913 to Test Safety and How the Drug Works in Healthy Adults Aged 18 to 65

What this Trial Is About

This trial evaluates the safety, pharmacokinetics, and pharmacodynamics of the drug RO7875913 in healthy adult volunteers aged 18 to 65 years. The study is designed as a Phase I dose-escalation trial to understand how the drug behaves in the body and its potential effects, involving both RO7875913 and placebo treatments. Participants are healthy individuals without major medical conditions, providing a controlled setting to assess the investigational drug. Participants are randomly assigned to receive either RO7875913 or a placebo in a sequential dose-escalation manner. The study uses quadruple masking to ensure unbiased assessment. Dosage and administration schedules follow the protocol, with detailed monitoring of drug concentration and immune response markers during treatment. This study includes a period of up to approximately three months for safety and pharmacodynamic evaluations. Throughout the trial, participants undergo assessments including monitoring for adverse events, blood tests to measure drug levels and antibody responses, and pharmacodynamic marker evaluations. Researchers closely track safety outcomes and determine recommended doses for future studies. Participation involves regular visits for dosing and evaluations, lasting up to three months in total, ensuring careful observation of participants health and response to the study drug.

A Dose-Escalation Study of RO7875913 in Healthy Participants